Glioma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The lower fatty acyl pool may be mediated by the lower protein expression levels of long-chain acyl-CoA synthetase 1 (ACSL1), ACSL4, and very long-chain acyl-CoA synthetase 3 (ACSVL3) in IDH1 mutant glioma.
|
30596429 |
2019 |
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Among the five family isoforms, ACSL1 and ACSL4 are able to promote ungoverned cell growth, facilitate tumor invasion and evade programmed cell death, while ACSL3 may have relatively complex functions in different types of cancer.
|
30008815 |
2018 |
Sarcoma
|
0.010 |
Biomarker
|
group |
BEFREE |
The endogenous subcellular localisations of the long chain fatty acid-activating enzymes ACSL3 and ACSL4 in sarcoma and breast cancer cells.
|
29450800 |
2018 |
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Among the five family isoforms, ACSL1 and ACSL4 are able to promote ungoverned cell growth, facilitate tumor invasion and evade programmed cell death, while ACSL3 may have relatively complex functions in different types of cancer.
|
30008815 |
2018 |
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Among the five family isoforms, ACSL1 and ACSL4 are able to promote ungoverned cell growth, facilitate tumor invasion and evade programmed cell death, while ACSL3 may have relatively complex functions in different types of cancer.
|
30008815 |
2018 |
Malignant neoplasm of soft tissue
|
0.010 |
Biomarker
|
group |
BEFREE |
The endogenous subcellular localisations of the long chain fatty acid-activating enzymes ACSL3 and ACSL4 in sarcoma and breast cancer cells.
|
29450800 |
2018 |
Hormone sensitive prostate cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A public database showed that ACSL3 level was higher in CRPC than in hormone-sensitive prostate cancer.
|
28771887 |
2017 |
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
High ACSL3 expression predicted a better prognosis in ovarian cancer; in contrast, high ACSL3 predicted a worse prognosis in melanoma.
|
27171439 |
2016 |
ovarian neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High ACSL3 expression predicted a better prognosis in ovarian cancer; in contrast, high ACSL3 predicted a worse prognosis in melanoma.
|
27171439 |
2016 |
Malignant neoplasm of ovary
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High ACSL3 expression predicted a better prognosis in ovarian cancer; in contrast, high ACSL3 predicted a worse prognosis in melanoma.
|
27171439 |
2016 |
Carcinoma, Ovarian Epithelial
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High ACSL3 expression predicted a better prognosis in ovarian cancer; in contrast, high ACSL3 predicted a worse prognosis in melanoma.
|
27171439 |
2016 |
Vascular calcification
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
These results identify ACSL3 and NF-κB as mediators of PA-induced osteoblastic differentiation and calcium deposition in VSMC and suggest that EPA prevents vascular calcification by inhibiting such a new molecular pathway elicited by PA.
|
23840832 |
2013 |
Childhood asthma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Relation of DNA methylation of 5'-CpG island of ACSL3 to transplacental exposure to airborne polycyclic aromatic hydrocarbons and childhood asthma.
|
19221603 |
2009 |
Hepatitis C
|
0.010 |
Biomarker
|
disease |
LHGDN |
These results identify ACSL3 as a new enzymatic target to limit VLDL secretion and HCV infection.
|
18003621 |
2008 |
Hepatitis C
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results identify ACSL3 as a new enzymatic target to limit VLDL secretion and HCV infection.
|
18003621 |
2008 |
Liver neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Long chain acyl-CoA synthetase 3-mediated phosphatidylcholine synthesis is required for assembly of very low density lipoproteins in human hepatoma Huh7 cells.
|
18003621 |
2008 |
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Long chain acyl-CoA synthetase 3-mediated phosphatidylcholine synthesis is required for assembly of very low density lipoproteins in human hepatoma Huh7 cells.
|
18003621 |
2008 |
Hyperlipidemia
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Transcriptional activation of hepatic ACSL3 and ACSL5 by oncostatin m reduces hypertriglyceridemia through enhanced beta-oxidation.
|
17761945 |
2007 |
Prostatic Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Vitamin D3 inhibits fatty acid synthase expression by stimulating the expression of long-chain fatty-acid-CoA ligase 3 in prostate cancer cells.
|
15556626 |
2004 |
Blepharoptosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Saethre-Chotzen syndrome (acrocephalo-syndactyly type III, ACS III) is an autosomal dominant craniosynostosis with brachydactyly, soft tissue syndactyly and facial dysmorphism including ptosis, facial asymmetry and prominent ear crura.
|
8988167 |
1997 |
Craniosynostosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Saethre-Chotzen syndrome (acrocephalo-syndactyly type III, ACS III) is an autosomal dominant craniosynostosis with brachydactyly, soft tissue syndactyly and facial dysmorphism including ptosis, facial asymmetry and prominent ear crura.
|
8988167 |
1997 |
Ptosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Saethre-Chotzen syndrome (acrocephalo-syndactyly type III, ACS III) is an autosomal dominant craniosynostosis with brachydactyly, soft tissue syndactyly and facial dysmorphism including ptosis, facial asymmetry and prominent ear crura.
|
8988167 |
1997 |
Syndactyly
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Saethre-Chotzen syndrome (acrocephalo-syndactyly type III, ACS III) is an autosomal dominant craniosynostosis with brachydactyly, soft tissue syndactyly and facial dysmorphism including ptosis, facial asymmetry and prominent ear crura.
|
8988167 |
1997 |
Brachydactyly
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Saethre-Chotzen syndrome (acrocephalo-syndactyly type III, ACS III) is an autosomal dominant craniosynostosis with brachydactyly, soft tissue syndactyly and facial dysmorphism including ptosis, facial asymmetry and prominent ear crura.
|
8988167 |
1997 |
Congenital anomaly of face
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Saethre-Chotzen syndrome (acrocephalo-syndactyly type III, ACS III) is an autosomal dominant craniosynostosis with brachydactyly, soft tissue syndactyly and facial dysmorphism including ptosis, facial asymmetry and prominent ear crura.
|
8988167 |
1997 |